Pasithea Therapeutics Corp. KTTA 深 沪
等待开盘 12-20 09:30:00 美东时间
1.15
+0.050
+4.55%
华盛通- 最 高2.06
- 今 开1.12
- 成交量 65.48万股
- 最 低 0.349
- 昨 收 1.10
- 总市值 2678.10万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 2.81%
- 52周最低 0.281
- 委 比 -55.23%
- 总股本 2328.78万
- 历史最高 9.25
- 量 比 0.93
- 振 幅 155.55%
- 历史最低 0.19
- 每 手 1
- 风险率 0.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Pasithea Therapeutics appoints Dr. James Lee to its SAB to guide development of PAS-004 for ETS2-driven diseases, including inflammatory bowel disease (IBD). Dr. Lee's research identified ETS2 as a key regulator of IBD inflammation and highlighted MEK inhibitors' effectiveness in suppressing it.
06-11 11:02
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004, a next-generation MEK inhibitor, shows early promise as monotherapy for heavily pre-treated, refractory solid tumors, with two patients achieving stable disease and tumor reductions of -9.8% and -14.9%. Its pharmacokinetic profile supports prolonged target engagement at tolerable doses.
06-02 12:02
康乃德生物盘中异动 下午盘快速拉升10.14%
北京时间2025年02月06日02时29分，康乃德生物（CNTB.us）股票出现异动，股价快速拉升10.14%。截至发稿，该股报1.075美元/股，成交量1.5786万股，换手率0.03%，振幅14.55%。 最近的财报数据显示，该股实现营业收入24.12百万美元，净利润7.65百万美元，每股收益0.14美元，毛利23.64百万美元，市盈率-2.61倍。 机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中，整体涨幅为2.09%。其相关个股中，Transcode Therapeutics, Inc.、Pasithe...
02-06 02:29
Dow Surges Over 250 Points; Accenture Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones index r...
2024-09-27 02:52
Crude Oil Down Over 2%; US Initial Jobless Claims Fall
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
2024-09-27 00:01
Nasdaq Gains Over 1%; Micron Posts Upbeat Q4 Results
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over ...
2024-09-26 21:48
Why Is Pasithea Therapeutics Stock Surging On Thursday?
Pasithea Therapeutics reports encouraging early Phase 1 data for PAS-004, showing no adverse events or toxicities. The trial highlights safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
2024-09-26 20:56
Market-Moving News for September 26th
MU: 17% | Micron shares are trading higher following better-than-expected Q4 financial results. TBIO: 148% | Telesis Bio Partners With Beckman Coulter Life Sciences To Revolutionize DNA And mRNA Synthesis,
2024-09-26 19:59
Pasithea Therapeutics Announces The Completion Of Long-Term Chronic Toxicity Studies In Both Rats And Dogs With Its Lead Candidate PAS-004, Currently Being Investigated In A Phase 1 Clinical Trial In Advanced Cancer Patients
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type
2024-09-09 20:20
